Preclinical evaluation of a synthetic Plasmodium falciparum MAP malaria vaccine in Aotus monkeys and mice

Vaccine

Volumn 18, Issue 1-2, 1999, Pages 89-99

  Moreno, C Alberto ^a   Rodriguez, Raúl ^a   Oliveira, Giane A ^b   Ferreira, Viviana ^b   Nussenzweig, Ruth S ^b   Moya Castro, Z Rosa ^b   Calvo Calle, J Mauricio ^b   Nardin, Elizabeth ^b  

^a Hospital San Juan de Dios   (Colombia)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Anti sporozoite antibody; Aotus spp; P. falciparum; Synthetic peptide vaccine

Indexed keywords

ANTIGEN; FREUND ADJUVANT; IMMUNOLOGICAL ADJUVANT;

ADULT; AMINO ACID SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ANTIBODY TITER; ANTIGEN ANTIBODY REACTION; ARTICLE; CONTROLLED STUDY; DRUG FORMULATION; DRUG SYNTHESIS; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; IMMUNIZATION; IMMUNOGENICITY; MALARIA; MONKEY; MOUSE; NONHUMAN; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL;

ALUM COMPOUNDS; ANIMALS; AOTUS TRIVIRGATUS; FREUND'S ADJUVANT; IMMUNIZATION; MALARIA VACCINES; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; PLASMODIUM FALCIPARUM; PROTOZOAN PROTEINS; SAPONINS; VACCINES, SYNTHETIC;

EID: 0033588527     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(99)00184-X     Document Type: Article

References (37)

1. Nussenzweig V., Nussenzweig R.S. Rationale for the development of an engineered sporozoite malaria vaccine. Adv Immunol. 45:1989;283-334.
2. Herrington D.A., Clyde D.F., Losonsky G., Cortesia M., Murphy J.R., Davis J., Baqar S., Felix A.M., Heimer E.P., Gillessen D., Nardin E., Nussenzweig R.S., Nussenzweig V., Hollingdale M.R., Levine M.M. Safety and immunogenicity in man of a synthetic peptide malaria vaccine against Plasmodium falciparum sporozoites. Nature. 328:1987;257-259.
3. Tam J.P., Clavijo P., Lu Y.A., Nussenzweig V., Nussenzweig R., Zavala F. Incorporation of T and B epitopes of the circumsporozoite protein in a chemically defined synthetic vaccine against malaria. J Exp Med. 171:1990;299-306.
4. Zavala F., Chai S. Protective anti-sporozoite antibodies induced by chemically defined synthetic vaccine. Immunol Lett. 25:1990;271-274.
5. Marussig M., Renia L., Motard A., Miltgen F., Petour P., Chauhan V., Corradin G., Mazier D. Linear and multiple antigen peptides containing defined T and B epitopes of the Plasmodium yoelii circumsporozoite protein: antibody-mediated protection and boosting by sporozoite infection. Internat Immunol. 9:1997;1817-1824.
6. Reed R.C., Louis-Wileman V., Cosmai E.V., Fang S., Jue D.L., Wohlhueter R.M., Hunter R.L., Lal A.A. Multiple antigen constructs (MACs): induction of sterile immunity against sporozoite stage of rodent malaria parasites, Plasmodium berghei and Plasmodium yoelii. Vaccine. 15:1997;482-488.
7. Wang R., Charoenvit Y., Corradin G., Porrozzi R., Hunter R.L., Glen G., Alving C.R., Church P., Hoffman S. Induction of protective polyclonal antibodies by immunization with a Plasmodium yoelii circumsporozoite protein multiple antigen peptide vaccine. J Immunol. 154:1995;2784-2793.
8. Yang C., Collins W.E., Xiao L., Saekhou A.M., Reed R.C., Nelson C.O., Hunter R.L., Jue D.L., Fang S., Wohlhueter R.M., Udhayakumar V., Lal A.A. Induction of protective antibodies in Saimiri monkeys by immunization with a multiple antigen construct (MAC) containing the Plasmodium vivax circumsporozoite protein repeat region and a universal T helper epitope of tetanus toxoid. Vaccine. 15:1997;377-386.
9. Munesinghe D.Y., Clavijo P., Calvo-Calle M., Nussenzweig R.S., Nardin E. Immunogenicity of multiple antigen peptides (MAP) containing T and B cell epitopes of the repeat region of the P. falciparum circumsporozoite protein. Eur J Immunol. 21:1991;3015-3020.
10. Calvo-Calle J.M., de Oliveira G.A., Clavijo P., Maracic M., Tam J.P., Lu Y.A., Nardin E.H., Nussenzweig R.S., Cochrane A.H. Immunogenicity of multiple antigen peptides containing B and non-repeat T cell epitopes of the circumsporozoite protein of Plasmodium falciparum. J Immunol. 150:1993;1403-1412.
11. + clones from a malaria-immunized volunteer. Science. 246:1989;1603-1606.
12. Collins W.E. The owl monkey as a model for malaria. Baer J.F., Weller R.E., Kakoma I. Aotus: the owl monkey. 1994;217-244 Academic Press, San Diego.
13. Collins W.E., Anders R.F., Pappaioanou M., Campbell G.H., Brown G.V., Kemp D.J., Coppel R.L., Skinner J.C., Andrysiak P., Favaloro J.M., Corcoran L.M., Broderson J.R., Mitchell G.F., Campbell C.C. Immunization of Aotus monkeys with recombinant proteins of an erythrocyte surface antigen of Plasmodium falciparum. Nature. 323:1986;259-262.
14. Patarroyo M.E., Romero P., Torres M.L., Clavijo P., Moreno A., Martinez A., Rodriguez R., Guzman F., Cabezas E. Induction of protective immunity against experimental infection with malaria using synthetic peptides. Nature. 328:1987;629-632.
15. Rodriguez R., Moreno A., Guzman F., Calvo M., Patarroyo M.E. Studies in owl monkeys leading to the development of a synthetic vaccine against the asexual blood stages of Plasmodium falciparum. Am J Trop Med Hyg. 43:1990;339-354.
16. Herrera S., Herrera M.A., Perlaza B.L., Burki Y., Caspers P., Dobeli H., Rotmann D., Certa U. Immunization of Aotus monkeys with Plasmodium falciparum blood stage recombinant proteins. Proc Nat Acad Sci. 87:1990;4017-4021.
17. Herrera M.A., Rosero F., Herrera S., Caspers P., Rotmann D., Sinigaglia F., Certa U. Protection against malaria in Aotus monkeys immunized with a recombinant blood-stage antigen fused to a universal T cell epitope: correlation of serum gamma interferon levels with protection. Inf Immun. 60:1992;154-158.
18. Inselburg J., Bathurst I.C., Kansopon J., Barr P.J., Rossan R. Protective immunity induced in Aotus monkeys by a recombinant SERA protein of Plasmodium falciparum: further studies using SERA 1 and MF75.2 adjuvant. Inf Immun. 61:1993;2048-2052.
19. Gramzinski R.A., Maris D.C., Obaldia N., Rossan R., Sedegah M., Wang R., Hobart P., Margalith M., Hoffman S. Optimization of antibody responses of a malaria DNA vaccine in Aotus monkeys. Vaccine Res. 5:1996;173-183.
20. Chang S.P., Case S.E., Gosnell W.L., Hashimoto A., Kramer K.J., Tam L.Q., Hashiro C.Q., Nikaido C.M., Gibson H.L., Lee-Ng C.T., Barr P.J., Yokota B.T., Hui G.S. A recombinant baculovirus 42-kilodalton C-terminal fragment of Plasmodium falciparum merozoite surface protein 1 protects Aotus monkeys against malaria. Inf Immun. 64:1996;253-261.
21. Perlaza B.L., Arevalo-Herrera M., Brahimi K., Quintero G., Palomino J.C., Gras-Masse H., Tartar A., Druilhe P., Herrera S. Immunogenicity of four Plasmodium falciparum pre-erythrocytic antigens in Aotus lemurinus monkeys. Inf Immun. 66:1998;3423-3428.
22. Ford S.M. Taxonomy and distribution of the owl monkey. Baer J.F., Weller R.E., Kakoma I. Aotus: The owl monkey. 1994;1-57 Academic Press, San Diego.
23. Tam J. Synthetic peptide vaccine design: synthesis and properties of a high density multiple antigenic peptide system. Proc Natl Acad Sci. 85:1988;5409-5413.
24. Kensil C.R., Patel U., Lennick M., Marciani D. Separation and characterization of saponins with adjuvant activity from Quillaja saponaria Molina cortex. J Immunol. 146:1991;431-437.
25. Kitamura K., Livingston P.O., Fortunato S.R., Stockert E., Helling F., Ritter G., Oettgen H.F., Old L.J. Serological response patterns of melanoma patients immunized with a GM2 ganglioside conjugate vaccine. Proc Natl Acad Sci. 92:1995;2805-2809.
26. Livingston P.O., Adluri S., Helling F., Yao T.-J., Kensil C.R., Newman M.J., Marciani D. Phase I trial of immunological adjuvant QS21 with a GM2 ganglioside-KLH conjugate vaccine in patients with malignant melanoma. Vaccine. 12:1994;1275-1280.
27. Coughlin R.T., Fish D., Mather T.N., Ma J., Pavia C., Bulger P. Protection of dogs from Lyme disease with a vaccine containing outer surface protein (Osp)A, OspB, and the saponin adjuvant QS21. J Infect Dis. 171:1995;1049-1052.
28. Marciani D.J., Kensil C.R., Beltz G.A., Hung C.H., Cronier J., Aubert A. Genetically engineered subunit vaccine against feline leukemia virus: protective immune response in cats. Vaccine. 9:1991;89-96.
29. de Oliveira G., Clavijo P., Nussenzweig R.S., Nardin E. Immunogenicity of an alum-adsorbed synthetic multiple-antigen peptide based on B- and T-cell epitopes of the Plasmodium falciparum CS protein: possible vaccine application. Vaccine. 12:1994;1012-1017.
30. Wu J.-Y., Gardner B.H., Murphy C.I., Seals J.R., Kensil C.R., Recchia J., Beltz G.A., Newman G.W., Newman M.J. Saponin adjuvant enhancement of antigen specific immune responses to an experimental HIV-1 vaccine. J Immunol. 148:1992;1519-1525.
31. Collins W.E., Nussenzweig R.S., Ruebush T.K., Bathurst I.C., Nardin E.H., Gibson H.L., Campbell G.H., Barr P.J., Broderson J.R., Skinner J.C., Filipski V.K., Stanfill G.S., Roberts J.M., Wilson C.L. Further studies on the immunization of Saimiri sciureus boliviensis with recombinant vaccines based on the circumsporozoite protein of Plasmodium vivax. Am J Trop Med Hyg. 43:1990;576-583.
32. del Guercio M.-F., Alexander J., Kubo R.T., Arrhenius T., Maewal A., Appella E., Hoffman S.L., Jones T., Valmori D., Sakaguchi K., Grey H.M., Sette A. Potent immunogenic short linear peptide constructs composed of B cell epitopes and Pan DR T helper epitopes (PADRE) for antibody responses in vivo. Vaccine. 15:1997;441-448.
33. Stoute J.A., Slaoui M., Heppner D.G., Momin P., Kester K.E., Desmons P., Wellde B.T., Garcon N., Krzych U., Marchand M., Ballou W.R., Cohen J.D. A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. N Engl J Med. 336:1997;86-91.
34. Trtkova K., Kupfermann H., Grahovac B., Mayer W.E., O'hUigin C., Tichy H., Bontrop R., Klein J. Mhc-DRB genes of platyrrhine primates. Immunogen. 38:1993;210-222.
35. + T cell clones obtained from Plasmodium falciparum sporozoite immunized volunteers recognize polymorphic sequences of the circumsporozoite protein. J Immunol. 151:1993;489-499.
36. Calvo-Calle J.M., Hammer J., Sinigaglia F., Clavijo P., Moya-Castro Z.R., Nardin E.H. Binding of malaria T cell epitopes to DR and DQ molecules in vitro correlates with immunogenicity in vivo. Identification of a universal T cell epitope in the Plasmodium falciparum circumsporozoite protein. J Immunol. 159:1997;1362-1373.
37. Nardin E.H., Calvo-Calle J.M., Oliveira G.A., Calvijo P., Nussenzweig R., Simon R., Zeng W., Rose K. Plasmodium falciparum polyoximes: highly immunogenic synthetic vaccines constructed by chemoselective ligation of repeat B cell epitopes and a universal T cell epitope of CS protein. Vaccine. 16:1998;590-600.